ADGRL3 SNP Detection for Mild Brain Injury Risk Assessment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic methods for mild traumatic brain injury (mTBI) rely solely on clinical evaluation, lacking genetic markers to assess susceptibility and severity, and there is a need for effective treatments to manage mTBI symptoms.

Innovation Solution

Detection of specific single nucleotide polymorphisms (SNPs) in the ADGRL3 gene, particularly rs1470721, to identify increased risk for mTBI, and administration of glutamatergic modulators like fasoracetam to treat and prevent mTBI.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If clinical evaluation alone is used for mTBI diagnosis, then the diagnostic process is simple and quick, but the precision and reliability of risk assessment are insufficient

Engineering Contradiction:

Improverisk assessment precisionVSAvoiddiagnostic method complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent introduces genetic markers (SNPs in ADGRL3 gene) as intermediary elements between clinical evaluation and mTBI risk assessment. These markers serve as mediators that provide objective, quantifiable data about genetic susceptibility, thereby improving measurement precision without requiring complete redesign of the diagnostic workflow

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The genetic testing method is designed to be universally applicable across different populations and can be integrated with existing clinical evaluation protocols. The same SNP detection approach works for both research and clinical settings, providing a multi-functional solution that addresses both precision and ease of operation

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If genetic markers are integrated into mTBI diagnosis, then the reliability of susceptibility assessment is improved, but the ease of operation and accessibility are reduced

Engineering Contradiction:

Improvesusceptibility assessment reliabilityVSAvoiddiagnostic procedure accessibility

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The diagnostic process is segmented into distinct modules: clinical evaluation and genetic testing. This segmentation allows each component to be optimized independently - clinical evaluation maintains its simplicity while genetic testing provides reliable susceptibility data. The modular approach enables flexible implementation based on resource availability

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses DNA copying (PCR amplification) to generate sufficient quantities of genetic material for analysis from small biological samples. This copying mechanism enables reliable genetic assessment without requiring large or invasive samples, thereby maintaining ease of operation while improving reliability

Inventive Principle:

Principle #26Copying

3Measurement precision

If SNP detection methods are used to identify mTBI risk, then the accuracy of risk identification is improved, but the time and resources required for testing increase

Engineering Contradiction:

Improverisk identification accuracyVSAvoidtesting time

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent identifies and focuses on specific, pre-determined SNP locations in the ADGRL3 gene that are most strongly associated with mTBI risk. This preliminary identification of target sites allows for direct, rapid testing at known locations rather than comprehensive genome-wide screening, significantly reducing testing time while maintaining high accuracy

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The testing methodology uses parameter changes in the detection process, such as allele-specific PCR conditions and fluorescent probe concentrations, to optimize the balance between accuracy and speed. By adjusting these parameters, the system achieves high-risk identification accuracy with minimized testing duration

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Provides a genetic basis for identifying mTBI risk and offers a therapeutic approach using glutamatergic modulators to manage mTBI symptoms effectively.

Implementation Method 1

endogenous proteolytic cleavage within a cysteine-rich GPS (G-protein-coupled-receptor proteolysis site) domain resulted in two subunits (a large extracellular N-terminal cell adhesion subunit and a subunit with substantial similarity to the secretin/calcitonin family of GPCRs) being non-covalently bound at the cell membrane

Methodology Applied

Scientific EffectProteolytic cleavage: Hydrolysis

Implementation Method 2

two subunits (a large extracellular N-terminal cell adhesion subunit and a subunit with substantial similarity to the secretin/calcitonin family of GPCRs) being non-covalently bound at the cell membrane

Methodology Applied

Scientific EffectNon-covalent binding: Van der Waals Force

Data Source

PatentUS20260071276A1GPCR latrophilin-3 as biomarker for detecting increased risk for mild brain injury and methods of use thereof for diagnosis and treatment of the same

Publication Date: 2026.03.12 THE CHILDRENS HOSPITAL OF PHILADELPHIA

AI summary

Compositions and methods for diagnosis and treatment of increased risk for mild traumatic brain injury are disclosed.